Best Growth Hormone Secretagogues in 2026: An Evidence-Based Ranking

How this ranking works

Growth hormone secretagogues are a structurally diverse category: GHRH analogs (sermorelin, CJC-1295, tesamorelin), GHRPs / ghrelin mimetics (ipamorelin, hexarelin, GHRP-2, GHRP-6), and small-molecule non-peptide secretagogues (MK-677). They all produce GH release through different receptors, with different durations, side-effect profiles, and evidence bases.

This ranking weights evidence quality, mechanism cleanness, and practical utility together. A compound with strong evidence in a narrow indication outranks one with broader use but thinner evidence. None of this is medical advice. GH therapy decisions involve clinical considerations that belong with an endocrinologist.

#1: Tesamorelin

Evidence: Strong (FDA-approved) · Best for: visceral fat reduction, narrow clinical indications

Tesamorelin (sold as Egrifta) is a stabilized GHRH analog FDA-approved specifically for the reduction of visceral abdominal fat in HIV-associated lipodystrophy. The clinical evidence is substantial — multiple Phase 3 trials demonstrating measurable visceral-fat reduction with manageable side effects. It is the only peptide on this list with FDA approval for a body-composition outcome.

Its position here despite the narrow approved indication reflects evidence strength: tesamorelin is the only compound on the list with controlled human Phase 3 data demonstrating a body-composition outcome. Off-label use for visceral fat outside the HIV indication is common in some clinical contexts but exists in a different evidence and access tier than the approved indication.

#2: CJC-1295 + Ipamorelin combination

Evidence: Well-established mechanism, limited combination trials · Best for: research-grade GH support

The CJC-1295 + ipamorelin combination is the most-used GH secretagogue stack in the research-peptide community. The pharmacology is well-understood: CJC-1295 (a GHRH analog) extends the amplitude and duration of natural GH pulses; ipamorelin (a ghrelin receptor agonist) adds new pulses on top of the natural rhythm. The two compounds activate complementary receptors on the same axis, and the combination produces deeper GH elevation than either alone — this is reasonably well-established in pharmacology literature.

Important distinction: CJC-1295 exists in two forms. CJC-1295 with DAC (Drug Affinity Complex) has a half-life of approximately 8 days and produces sustained elevation. CJC-1295 without DAC (modified GRF 1-29) has a half-life of about 30 minutes and produces pulsatile elevation closer to physiological GH rhythm. Which form is preferred depends on the goal: sustained elevation may produce more downstream IGF-1; pulsatile elevation more closely mimics natural physiology. See our GHRH analog comparison for the detail.

#3: Sermorelin

Evidence: Historically FDA-approved · Best for: physiological GH support with shorter duration

Sermorelin is the GHRH(1-29) fragment — the shortest segment of natural GHRH retaining biological activity. It was FDA-approved as Geref in 1997 for pediatric growth hormone deficiency, then withdrawn in 2008 for commercial reasons (not safety). It remains available through compounding pharmacies under physician oversight.

Sermorelin produces a brief, physiological GH pulse with a half-life of approximately 30 minutes. The shorter duration is sometimes positioned as an advantage (closer to natural rhythm, lower potential for HPA axis disruption) and sometimes a disadvantage (less convenient dosing, smaller cumulative effect). It is the conservative, clinically-experienced choice in the GHRH analog category.

#4: Ipamorelin (alone)

Evidence: Established mechanism, minimal spillover · Best for: clean GH secretagogue without cortisol/prolactin effects

Ipamorelin is a selective GH-releasing peptide (a ghrelin receptor agonist) with the cleanest receptor selectivity in its class. Unlike GHRP-2 and GHRP-6, ipamorelin produces minimal increases in cortisol, prolactin, or aldosterone — making it the preferred choice when avoiding HPA axis activation is important.

Used alone, ipamorelin produces moderate GH pulses. Used with a GHRH analog (CJC-1295 most commonly), it produces synergistic GH elevation. Its position here reflects the value of having a clean tool when minimal off-target effects matter.

#5: Hexarelin

Evidence: Established but less-used than ipamorelin · Best for: stronger acute GH release

Hexarelin is a more potent ghrelin receptor agonist than ipamorelin, producing larger acute GH pulses. The trade-off is more receptor desensitization with prolonged use — sustained hexarelin dosing produces diminishing returns more quickly than ipamorelin does. It also produces more cortisol and prolactin elevation than ipamorelin, similar to GHRP-2 and GHRP-6.

It earns its position for the specific niche where acute potency matters more than long-term receptor sensitivity. For continuous research-grade use, ipamorelin is more common; for short courses or specific application windows, hexarelin has its uses.

#6: MK-677 / Ibutamoren

Evidence: Multiple human trials, real efficacy with real trade-offs · Best for: oral non-peptide GH support

MK-677 (ibutamoren) is a small-molecule (non-peptide) ghrelin receptor agonist, originally developed by Merck and studied through Phase 2 trials for sarcopenia and growth hormone deficiency. It is orally bioavailable, has a long half-life, and produces sustained GH and IGF-1 elevation.

The trade-offs are real and dose-dependent: water retention, increased appetite (the ghrelin receptor is the hunger hormone receptor, so appetite increase is expected mechanism), and in some users, lethargy or insulin sensitivity changes. Phase 2 trials in elderly patients showed real lean-mass gains alongside these side effects.

MK-677 is the most-used non-prescription oral option for GH support in performance and bodybuilding communities. Its non-peptide chemistry (it is a small molecule, not a peptide) means it falls outside the 'peptide' regulatory category that applies to most others on this list. See our MK-677 page for the detail.

The GHRP-2 and GHRP-6 question

GHRP-2 and GHRP-6 are older ghrelin-receptor agonists that produced the proof-of-concept for GH-releasing peptides as a class. Both are still used in research-peptide communities, but for most modern use cases ipamorelin has displaced them because of its cleaner selectivity (less cortisol and prolactin spillover). Our detailed comparison covers when each is preferred. They are not on the main ranking because for general use cases, ipamorelin is generally preferred.

What about HGH itself?

Recombinant human growth hormone (somatropin) is the FDA-approved drug for GH deficiency. It is the direct delivery of GH rather than the secretagogue approach of releasing endogenous GH. It is much stronger pharmacologically and much more strictly regulated. For diagnosed adult GH deficiency, it is the standard of care. For non-deficient performance use, it carries Schedule III restrictions and significant legal exposure that the secretagogues on this list do not (in most jurisdictions). The secretagogue strategy works with the body's natural pulsatile GH rhythm; direct HGH bypasses it.

The honest bottom line

For visceral fat specifically and narrow clinical indications, tesamorelin is the evidence-based choice — the only compound on this list with FDA approval for a body-composition outcome. For research-grade GH support with established pharmacology, CJC-1295 + ipamorelin remains the most-used and best-understood stack. For oral non-peptide use, MK-677 has the longest accumulated human data with real trade-offs. The 'best' depends entirely on the goal, the regulatory pathway preferred, and on whether clinical supervision is part of the plan.